复发缓解型多发性硬化治疗策略:升级治疗与起始高效治疗的国家队列比较
该队列研究纳入丹麦和瑞典国家多发性硬化登记库中2013至2016年起始疾病修正治疗的4861例复发缓解型多发性硬化患者,比较两国不同治疗策略与残疾结局的关联。瑞典策略更多起始高效治疗,与丹麦策略相比,24周确认残疾恶化风险降低29%,并更少达到EDSS 3分和4分里程碑。
要点
- 起始高效治疗策略与更低的24周确认残疾恶化风险相关,优于升级治疗策略。
- 瑞典策略中34.5%患者起始高效治疗,丹麦仅7.6%,两国策略差异明显。
- 瑞典策略还降低达到EDSS 3分和4分的风险,提示早期高效治疗可能延缓残疾进展。
核心结论
- 在国家级层面,复发缓解型多发性硬化的治疗策略差异与残疾结局相关,起始高效治疗优于升级治疗策略。
主要发现
- 丹麦92.3%患者起始低至中等疗效治疗,7.6%起始高效治疗;瑞典65.5%起始低至中等疗效治疗,34.5%起始高效治疗。
关键数值与推荐
- 主要结局为24周确认残疾恶化时间,次要结局包括24周确认残疾改善、EDSS 3分和4分里程碑、年化复发率、首次复发时间和治疗转换。
- 丹麦队列2161例,瑞典队列2700例,观察期平均4.1年(SD 1.5)。
临床怎么用
- 对于复发缓解型多发性硬化患者,可考虑起始高效疾病修正治疗而非逐步升级,以降低残疾恶化风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Treatment strategies for relapsing-remitting multiple sclerosis (RRMS) vary markedly between Denmark and Sweden. The difference in the association of these national strategies with clinical outcomes is unknown. OBJECTIVE: To investigate the association of national differences in disease-modifying treatment (DMT) strategies for RRMS with disability outcomes. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used data on 4861 patients from the Danish and Swedish national multiple sclerosis (MS) registries from the date of index DMT initiation (between January 1, 2013, and December 31, 2016) until the last recorded visit at time of data extraction (October 2, 2019). EXPOSURES: All MS-specific DMTs initiated during the observation period were included in the analysis. MAIN OUTCOMES AND MEASURES: The primary study outcome was time to 24-week confirmed disability worsening. Secondary outcomes were 24-week confirmed disability improvement, milestone Expanded Disability Status Scale scores of 3 and 4, annualized relapse rate, time to first relapse, and treatment switching. Data were analyzed using inverse probability of treatment weighting-based models using a propensity score to weight and correct the comparison for the imbalance of confounders observed at baseline between the 2 countries. RESULTS: A total of 2700 patients from the Swedish MS registry (1867 women [69.2%]; mean [SD] age, 36.1 [9.5] years) and 2161 patients from the Danish MS registry (1472 women [68.1%]; mean [SD] age, 37.3 [9.4 years]) started a first DMT between 2013 and 2016, were included in the analysis, and were observed for a mean (SD) of 4.1 (1.5) years. A total of 1994 Danish patients (92.3%) initiated a low to moderately effective DMT (teriflunomide, 907 [42.0%]) and 165 (7.6%) initiated a highly effective DMT, whereas a total of 1769 Swedish patients (65.5%) initiated a low to moderately effective DMT (teriflunomide, 64 [2.4%]) and 931 (34.5%) initiated a highly effective DMT. The Swedish treatment strategy was associated with a 29% reduction in the rate of postbaseline 24-week confirmed disability worsening relative to the Danish treatment strategy (hazard ratio, 0.71; 95% CI, 0.57-0.90; P = .004). The Swedish treatment strategy was also associated with a 24% reduction in the rate of reaching an expanded disability status scale score of 3 (hazard ratio, 0.76; 95% CI, 0.60-0.97; P = .03) and a 25% reduction in the rate of reaching an expanded disability status scale score of 4 (hazard ratio, 0.75; 95% CI, 0.61-0.96; P = .01) relative to Danish patients. CONCLUSIONS AND RELEVANCE: The findings of this study suggest that there is an association between differences in treatment strategies for RRMS and disability outcomes at a national level. Escalation of treatment efficacy was inferior to using more efficacious DMT as initial treatment.
引用
- Spelman T, Magyari M, Piehl F, et al. Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies. JAMA Neurol. 2021. PMID: 34398221. doi:10.1001/jamaneurol.2021.2738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。